Anaplastic Large Cell Lymphoma (ALCL) is an indication for drug development with over 100 pipeline drugs currently active. According to GlobalData, preregistered drugs for Anaplastic Large Cell Lymphoma (ALCL) have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Anaplastic Large Cell Lymphoma (ALCL) compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Anaplastic Large Cell Lymphoma (ALCL) overview

Anaplastic Large Cell Lymphoma (ALCL) is a rare and aggressive type of non-Hodgkin lymphoma, involving abnormal growth of immune cells called lymphocytes. ALCL can affect the lymph nodes, skin, and other organs, often presenting as swollen lymph nodes or skin lumps. Two main subtypes exist: one linked to a genetic mutation and the other associated with breast implants. Treatment involves chemotherapy, radiation, and sometimes stem cell transplantation. Prognosis varies based on the subtype and stage, with some cases showing good response to treatment. Regular monitoring and personalized therapies are crucial due to the diverse nature of this lymphoma.

For a complete picture of PTSR and LoA scores for drugs in Anaplastic Large Cell Lymphoma (ALCL), buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.